Effects of prostacyclin injections and infusions on canine femoral hemodynamics

Thomas Campion, Thomas Gerald Lynch, John C. Kerr, Robert W. Hobson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The use of prostacyclin (PGI2) infusions has been recommended in the management of patients with severe distal arteriopathy, who are not candidates for conventional bypass procedures. Further clarification regarding the route of administration and the optimal dose of this potent vasodilator, however, is needed before controlled clinical trials are initiated. We measured bilateral femoral arterial blood flow electromagnetically in seven anesthetized adult mongrel dogs. Systemic arterial pressure and cardiac output were also measured. Central venous and femoral arterial injections of PGI2 were administered in five doses ranging from 10-4 to 100 μg · kg-1 to study the dose response. PGI2 was also infused intravenously and intra-arterially for 20 minutes at a dose of 10-1 μg · kg-1 · min-1. Femoral arterial injections of PGI2 in doses from 10-4 through 100 μg · kg-1 caused significant (p < 0.05) and dose-dependent increases in ipsilateral femoral arterial blood flow. Intravenous injections of PGI2 caused no significant changes in the dose range from 10-4 to 10-2 μg · kg-1 but resulted in a significant (p < 0.05) reduction in femoral arterial flow and systemic arterial pressure at doses of 10-1 and 100 μg · kg-1. The femoral arterial infusion of PGI2 produced a significant and sustained increase in femoral arterial flow that was not observed during the intravenous infusion. Arterial pressure was unchanged with intra-arterial PGI2 but was significantly reduced during the intravenous infusion. The beneficial hemodynamic effects of intra-arterial PGI2 suggest that further clinical trials should employ this route of administration. On the basis of these data, intravenous administration of the drug will have limited clinical application.

Original languageEnglish (US)
Pages (from-to)540-544
Number of pages5
JournalJournal of vascular surgery
Volume3
Issue number3
DOIs
StatePublished - Jan 1 1986

Fingerprint

Epoprostenol
Thigh
Canidae
Hemodynamics
Injections
Arterial Pressure
Intravenous Infusions
Controlled Clinical Trials
Vasodilator Agents
Intravenous Injections
Intravenous Administration
Cardiac Output
Clinical Trials
Dogs

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of prostacyclin injections and infusions on canine femoral hemodynamics. / Campion, Thomas; Lynch, Thomas Gerald; Kerr, John C.; Hobson, Robert W.

In: Journal of vascular surgery, Vol. 3, No. 3, 01.01.1986, p. 540-544.

Research output: Contribution to journalArticle

Campion, Thomas ; Lynch, Thomas Gerald ; Kerr, John C. ; Hobson, Robert W. / Effects of prostacyclin injections and infusions on canine femoral hemodynamics. In: Journal of vascular surgery. 1986 ; Vol. 3, No. 3. pp. 540-544.
@article{800070e5ccbd4adfa1279b871f27eef1,
title = "Effects of prostacyclin injections and infusions on canine femoral hemodynamics",
abstract = "The use of prostacyclin (PGI2) infusions has been recommended in the management of patients with severe distal arteriopathy, who are not candidates for conventional bypass procedures. Further clarification regarding the route of administration and the optimal dose of this potent vasodilator, however, is needed before controlled clinical trials are initiated. We measured bilateral femoral arterial blood flow electromagnetically in seven anesthetized adult mongrel dogs. Systemic arterial pressure and cardiac output were also measured. Central venous and femoral arterial injections of PGI2 were administered in five doses ranging from 10-4 to 100 μg · kg-1 to study the dose response. PGI2 was also infused intravenously and intra-arterially for 20 minutes at a dose of 10-1 μg · kg-1 · min-1. Femoral arterial injections of PGI2 in doses from 10-4 through 100 μg · kg-1 caused significant (p < 0.05) and dose-dependent increases in ipsilateral femoral arterial blood flow. Intravenous injections of PGI2 caused no significant changes in the dose range from 10-4 to 10-2 μg · kg-1 but resulted in a significant (p < 0.05) reduction in femoral arterial flow and systemic arterial pressure at doses of 10-1 and 100 μg · kg-1. The femoral arterial infusion of PGI2 produced a significant and sustained increase in femoral arterial flow that was not observed during the intravenous infusion. Arterial pressure was unchanged with intra-arterial PGI2 but was significantly reduced during the intravenous infusion. The beneficial hemodynamic effects of intra-arterial PGI2 suggest that further clinical trials should employ this route of administration. On the basis of these data, intravenous administration of the drug will have limited clinical application.",
author = "Thomas Campion and Lynch, {Thomas Gerald} and Kerr, {John C.} and Hobson, {Robert W.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1016/0741-5214(86)90123-0",
language = "English (US)",
volume = "3",
pages = "540--544",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of prostacyclin injections and infusions on canine femoral hemodynamics

AU - Campion, Thomas

AU - Lynch, Thomas Gerald

AU - Kerr, John C.

AU - Hobson, Robert W.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The use of prostacyclin (PGI2) infusions has been recommended in the management of patients with severe distal arteriopathy, who are not candidates for conventional bypass procedures. Further clarification regarding the route of administration and the optimal dose of this potent vasodilator, however, is needed before controlled clinical trials are initiated. We measured bilateral femoral arterial blood flow electromagnetically in seven anesthetized adult mongrel dogs. Systemic arterial pressure and cardiac output were also measured. Central venous and femoral arterial injections of PGI2 were administered in five doses ranging from 10-4 to 100 μg · kg-1 to study the dose response. PGI2 was also infused intravenously and intra-arterially for 20 minutes at a dose of 10-1 μg · kg-1 · min-1. Femoral arterial injections of PGI2 in doses from 10-4 through 100 μg · kg-1 caused significant (p < 0.05) and dose-dependent increases in ipsilateral femoral arterial blood flow. Intravenous injections of PGI2 caused no significant changes in the dose range from 10-4 to 10-2 μg · kg-1 but resulted in a significant (p < 0.05) reduction in femoral arterial flow and systemic arterial pressure at doses of 10-1 and 100 μg · kg-1. The femoral arterial infusion of PGI2 produced a significant and sustained increase in femoral arterial flow that was not observed during the intravenous infusion. Arterial pressure was unchanged with intra-arterial PGI2 but was significantly reduced during the intravenous infusion. The beneficial hemodynamic effects of intra-arterial PGI2 suggest that further clinical trials should employ this route of administration. On the basis of these data, intravenous administration of the drug will have limited clinical application.

AB - The use of prostacyclin (PGI2) infusions has been recommended in the management of patients with severe distal arteriopathy, who are not candidates for conventional bypass procedures. Further clarification regarding the route of administration and the optimal dose of this potent vasodilator, however, is needed before controlled clinical trials are initiated. We measured bilateral femoral arterial blood flow electromagnetically in seven anesthetized adult mongrel dogs. Systemic arterial pressure and cardiac output were also measured. Central venous and femoral arterial injections of PGI2 were administered in five doses ranging from 10-4 to 100 μg · kg-1 to study the dose response. PGI2 was also infused intravenously and intra-arterially for 20 minutes at a dose of 10-1 μg · kg-1 · min-1. Femoral arterial injections of PGI2 in doses from 10-4 through 100 μg · kg-1 caused significant (p < 0.05) and dose-dependent increases in ipsilateral femoral arterial blood flow. Intravenous injections of PGI2 caused no significant changes in the dose range from 10-4 to 10-2 μg · kg-1 but resulted in a significant (p < 0.05) reduction in femoral arterial flow and systemic arterial pressure at doses of 10-1 and 100 μg · kg-1. The femoral arterial infusion of PGI2 produced a significant and sustained increase in femoral arterial flow that was not observed during the intravenous infusion. Arterial pressure was unchanged with intra-arterial PGI2 but was significantly reduced during the intravenous infusion. The beneficial hemodynamic effects of intra-arterial PGI2 suggest that further clinical trials should employ this route of administration. On the basis of these data, intravenous administration of the drug will have limited clinical application.

UR - http://www.scopus.com/inward/record.url?scp=0022649993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022649993&partnerID=8YFLogxK

U2 - 10.1016/0741-5214(86)90123-0

DO - 10.1016/0741-5214(86)90123-0

M3 - Article

VL - 3

SP - 540

EP - 544

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 3

ER -